Internalization routes of cell-penetrating melanoma antigen peptides into human dendritic cells

Experimental Dermatology

Volumn 23, Issue 1, 2014, Pages 20-26

  Buhl, Timo ^a   Braun, Andrea ^a   Forkel, Susann ^a   Möbius, Wiebke ^a,b   van Werven, Lars ^b   Jahn, Olaf ^b   Rezaei Ghaleh, Nasrollah ^c,d   Zweckstetter, Markus ^a,c,d   Mempel, Martin ^a   Schön, Michael P ^a   Haenssle, Holger A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Cell penetrating peptides; Cellular immunotherapy; Dendritic cells; Melan A Mart 1; TAT

Indexed keywords

CELL PENETRATING PEPTIDE; MELAN A;

ARTICLE; CELL COMPARTMENTALIZATION; CELL MATURATION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; ENDOCYTOSIS; ENDOSOME; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTERNALIZATION; LEUKEMIA CELL LINE; LYSOSOME; PINOCYTOSIS; PROTEIN TRANSPORT; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL-PENETRATING PEPTIDES; CELLULAR IMMUNOTHERAPY; DENDRITIC CELLS; MELAN-A/MART-1; TAT;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; CELL DIFFERENTIATION; CELL LINE; CELL-PENETRATING PEPTIDES; DENDRITIC CELLS; ENDOCYTOSIS; ENDOSOMES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; JURKAT CELLS; LYSOSOMES; MART-1 ANTIGEN; MOLECULAR SEQUENCE DATA; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TEMPERATURE;

EID: 84891351398     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12285     Document Type: Article

References (45)

1. Steinman R M, Banchereau J. Nature 2007: 449: 419-426.
2. Finn O J. N Engl J Med 2008: 358: 2704-2715.
3. Bhargava A, Mishra D, Banerjee S et al. Immunotherapy 2012: 4: 703-718.
4. Chromik J, Schnurer E, Georg Meyer R et al. J Immunol Methods 2006: 308: 77-89.
5. Joffre O P, Segura E, Savina A et al. Nat Rev 2012: 12: 557-569.
6. Gromme M, Uytdehaag F G, Janssen H et al. Proc Natl Acad Sci USA 1999: 96: 10326-10331.
7. Verdijk P, Aarntzen E H, Lesterhuis W J et al. Clin Cancer Res 2009: 15: 2531-2540.
8. Ludewig B, McCoy K, Pericin M et al. J Immunol 2001: 166: 3678-3687.
9. Wang H Y, Wang R F. Adv Immunol 2012: 114: 151-176.
10. Duchardt F, Fotin-Mleczek M, Schwarz H et al. Traffic 2007: 8: 848-866.
11. Dietz G P, Bahr M. Methods Mol Biol 2007: 399: 181-198.
12. Shibagaki N, Okamoto T, Mitsui H et al. J Dermatol Sci 2011: 61: 153-161.
13. Haenssle H A, Riedl P, Buhl T et al. Exp Dermatol 2010: 19: 19-28.
14. Trabulo S, Cardoso A L, Cardoso A M et al. Curr Pharm Des 2013: 19: 2895-2923.
15. Raagel H, Saalik P, Pooga M. Biochim Biophys Acta 2010: 1798: 2240-2248.
16. Madani F, Lindberg S, Langel U et al. J Biophys 2011: 2011: 414729.
17. Poon G M, Gariepy J. Biochem Soc Trans 2007: 35: 788-793.
18. Richard J P, Melikov K, Brooks H et al. J Biol Chem 2005: 280: 15300-15306.
19. Amand H L, Rydberg H A, Fornander L H et al. Biochim Biophys Acta 2012: 1818: 2669-2678.
20. Kaplan I M, Wadia J S, Dowdy S F. J Control Release 2005: 102: 247-253.
21. Amand H L, Fant K, Norden B et al. Biochem Biophys Res Commun 2008: 371: 621-625.
22. Wadia J S, Stan R V, Dowdy S F. Nat Med 2004: 10: 310-315.
23. Tunnemann G, Martin R M, Haupt S et al. FASEB J 2006: 20: 1775-1784.
24. Edenhofer F. Curr Pharm Des 2008: 14: 3628-3636.
25. Foerg C, Merkle H P. J Pharm Sci 2008: 97: 144-162.
26. Kronenberg K, Brosch S, Butsch F et al. J Invest Dermatol 2010: 130: 2602-2610.
27. Monini P, Cafaro A, Srivastava I K et al. PLoS ONE 2012: 7: e48781.
28. Fayolle C, Davi M, Dong H et al. Vaccine 2010: 28: 6930-6941.
29. Shibagaki N, Udey M C. Eur J Immunol 2003: 33: 850-860.
30. Buhl T, Legler T J, Rosenberger A et al. Cancer Immunol Immunother 2012: 61: 2021-2031.
31. Haenssle H, Buhl T, Knudsen S et al. Exp Dermatol 2008: 17: 177-187.
32. Koivusalo M, Welch C, Hayashi H et al. J Cell Biol 2010: 188: 547-563.
33. Hawtrey A, Joubert D, van Jaarsveld P et al. Drug Deliv 2002: 9: 47-53.
34. Ziegler A, Nervi P, Durrenberger M et al. Biochemistry 2005: 44: 138-148.
35. Underhill D M, Goodridge H S. Nat Rev 2012: 12: 492-502.
36. Geissmann F, Gordon S, Hume D A et al. Nat Rev 2010: 10: 453-460.
37. Mitchell D J, Kim D T, Steinman L et al. J Pept Res 2000: 56: 318-325.
38. Jones S W, Christison R, Bundell K et al. Br J Pharmacol 2005: 145: 1093-1102.
39. Fretz M, Jin J, Conibere R et al. J Control Release 2006: 116: 247-254.
40. Neefjes J, Jongsma M L, Paul P et al. Nat Rev 2011: 11: 823-836.
41. Rock K L, Shen L. Immunol Rev 2005: 207: 166-183.
42. Ruutu M P, Chen X, Joshi O et al. Exp Dermatol 2011: 20: 534-536.
43. Brewer J M, Pollock K G, Tetley L et al. J Immunol 2004: 173: 6143-6150.
44. Rettig L, Haen S P, Bittermann A G et al. Blood 2010: 115: 4533-4541.
45. Mitsui H, Okamoto T, Kanzaki M et al. Br J Dermatol 2010: 162: 29-41.